Properties (93)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
biotechnology company
|
| gptkbp:advertising |
focused on innovation.
targeted therapies. |
| gptkbp:awards |
various industry recognitions.
|
| gptkbp:benefits |
aims to revolutionize treatment.
|
| gptkbp:businessModel |
collaborative development.
|
| gptkbp:CEO |
gptkb:Kevin_O'Connor
|
| gptkbp:clinicalTrials |
ongoing
improve patient outcomes. aims for breakthrough therapies. focused on genetic disorders. in gene therapy. preclinical. rare diseases. to address unmet needs. various stages. |
| gptkbp:collaborations |
academic institutions
with universities. leading research institutions. with healthcare providers. with industry leaders. with leading organizations. |
| gptkbp:community_engagement |
active in local initiatives.
|
| gptkbp:community_outreach |
engages with local communities.
|
| gptkbp:community_service |
innovative approaches.
aims to improve lives. collaborates with organizations. |
| gptkbp:contributedTo |
to the field of gene therapy.
|
| gptkbp:employees |
over 100
|
| gptkbp:financials |
venture capital.
|
| gptkbp:focus |
gene therapy
|
| gptkbp:founded |
2018
|
| gptkbp:founder |
gptkb:Kevin_O'Connor
|
| gptkbp:funding |
$100 million
diverse and robust. secured from investors. |
| gptkbp:future_plans |
to enhance patient care.
advancing genetic medicine. expand clinical trials. to transform healthcare. |
| gptkbp:futurePlans |
leading in gene therapy.
|
| gptkbp:headquarters |
gptkb:Cambridge,_Massachusetts
|
| gptkbp:healthcare |
drives advancements.
prioritizes patient needs. |
| https://www.w3.org/2000/01/rdf-schema#label |
Tessera Therapeutics
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:influence |
aims to reach worldwide.
|
| gptkbp:innovation |
driven by technology.
in gene therapy. |
| gptkbp:investmentFocus |
gptkb:Sofinnova_Partners
gptkb:Bessemer_Venture_Partners gptkb:Canaan_Partners GV F-Prime Capital transparent communication. |
| gptkbp:leadership |
experienced executives.
in the biotechnology field. |
| gptkbp:leads |
TBD.
|
| gptkbp:market |
biotechnology sector.
|
| gptkbp:mission |
transform lives through gene therapy.
|
| gptkbp:notableFeature |
in genetic engineering.
|
| gptkbp:partnerships |
Novartis
biopharmaceutical companies. |
| gptkbp:patentCitation |
multiple granted.
|
| gptkbp:platforms |
Gene_Writing.
|
| gptkbp:products |
focused on unmet medical needs.
|
| gptkbp:publications |
contributed to the field.
|
| gptkbp:regulatoryCompliance |
not yet approved.
proactive engagement. |
| gptkbp:research |
genetic medicine
actively participates. cutting-edge. focused on gene editing. focused on rare diseases. |
| gptkbp:research_focus |
cutting-edge technologies.
on genetic therapies. on innovative treatments. |
| gptkbp:scientificName |
upholds high standards.
|
| gptkbp:social_responsibility |
committed to ethical practices.
dedicated to ethical standards. |
| gptkbp:specialties |
in gene therapy.
|
| gptkbp:supportRole |
experts in gene therapy.
|
| gptkbp:targets |
genetic diseases
|
| gptkbp:team |
diverse and skilled.
|
| gptkbp:technique |
Gene Writing technology.
|
| gptkbp:technology |
DNA-based therapies
in gene editing. in genetic research. to lead in biotechnology. Gene_Writing |
| gptkbp:tributaryOf |
multiple candidates.
|
| gptkbp:vision |
pioneering the future of medicine.
|
| gptkbp:website |
www.tesseratherapeutics.com
|